Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Short-term Investments (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Short-term Investments for 16 consecutive years, with $912000.0 as the latest value for Q3 2025.

  • For Q3 2025, Short-term Investments changed N/A year-over-year to $912000.0; the TTM value through Sep 2025 reached $912000.0, changed N/A, while the annual FY2021 figure was $197.7 million, 61.25% down from the prior year.
  • Short-term Investments hit $912000.0 in Q3 2025 for Sangamo Therapeutics, roughly flat from $916000.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $464.1 million in Q1 2021 and bottomed at $912000.0 in Q3 2025.
  • Average Short-term Investments over 5 years is $185.1 million, with a median of $197.7 million recorded in 2021.
  • Year-over-year, Short-term Investments surged 82.25% in 2021 and then crashed 65.48% in 2023.
  • Sangamo Therapeutics' Short-term Investments stood at $197.7 million in 2021, then rose by 10.79% to $219.0 million in 2022, then plummeted by 65.48% to $75.6 million in 2023, then tumbled by 98.79% to $916000.0 in 2024, then fell by 0.44% to $912000.0 in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $912000.0, $916000.0, and $75.6 million for Q3 2025, Q1 2024, and Q3 2023 respectively.